Search results
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 7 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace· 11 hours agoInvestors concerned about broader market undulations may want to consider the resilience narrative...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks· 7 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 1.9% over this ...
AbbVie Inc Share Price | BVMF: ABBV34 Stock - Investing.com UK
Investing.com· 2 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
...NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA (NYSE:FIX), ...
Benzinga· 4 days agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 5 days agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
Barrons.com· 8 hours agoShares of Teva Pharmaceutical Industries have done something unusual this year: They’ve gone up. The...
YUNGBLUD Challenges the Misconceptions Surrounding Mental Health Improvement: Podcast
Consequence of Sound via Yahoo News· 14 hours agoThe artist pushes back against the idea that one might lose their "true self" when addressing their...
Earnings call: Enanta Pharmaceuticals Q2 fiscal results and pipeline updates By Investing.com
Investing.com· 12 hours agoEnanta Pharmaceuticals (NASDAQ: NASDAQ:ENTA), a biopharmaceutical company focused on developing oral...
In re Cellect Poses an Obvious Dilemma | JD Supra
JD Supra· 22 hours agoIn August 2023, the Federal Circuit in In re Cellect held that in evaluating unpatentability for obviousness-type double patenting (ODP) of a patent...